Vifor v. MSN Laboratories: Six-Patent Injectafer® ANDA Dispute Consolidated in D.N.J.
Swiss pharmaceutical IP holder Vifor (International) AG filed a Hatch-Waxman patent infringement action against Indian generics manufacturer MSN Laboratories over its ANDA referencing Injectafer® (ferric carboxymaltose injection) across six patents. The case was consolidated by consent of all parties after just 82 days, signalling coordinated multi-case management in a high-stakes IV iron sector dispute.
Six-patent Injectafer® ANDA battle consolidated in New Jersey
On April 25, 2025, Vifor (International) AG filed a patent infringement action in the U.S. District Court for the District of New Jersey against MSN Laboratories Private Limited, an Indian generics manufacturer. The complaint asserted six U.S. patents — US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2 — covering ferric carboxymaltose formulations and therapeutic uses. The accused products are MSN’s ANDA-referenced versions of Injectafer®, Vifor’s branded intravenous iron replacement therapy available in 100 mg, 500 mg, 750 mg, and 1 g iron concentrations.
The case did not reach a substantive merits ruling. On July 15, 2025, the parties jointly wrote to the Court requesting consolidation with related matters. The Court, satisfied that good cause existed and that all parties consented, ordered consolidation on July 16, 2025. This terminated the standalone docket after 82 days. Consolidation is a procedural step — it does not adjudicate infringement or validity, and both parties retain their full positions in the consolidated proceeding.
The swift move to consolidation after less than three months is consistent with multi-defendant Hatch-Waxman litigation patterns, where brand holders often sue multiple ANDA filers simultaneously and courts routinely merge overlapping dockets for efficiency. The public record does not disclose whether additional ANDA filers are involved, which specific case this docket was consolidated into, or whether any licensing or settlement discussions are underway. The six-patent portfolio breadth — spanning composition, formulation, and method claims — suggests Vifor is deploying a layered enforcement strategy typical of blockbuster IV iron products facing generic entry.
Filing to Case Consolidated in 82 days
82 days to consolidation — well below average ANDA district court litigation timelines
Case consolidated by consent: what this means for both parties
Consolidation merges dockets — litigation continues
Case consolidation under Fed. R. Civ. P. 42(a) allows a court to combine actions involving common questions of law or fact. Here, all parties consented. The standalone docket (3:25-cv-03286) closes, but the claims, defences, and patents-in-suit carry forward into the consolidated proceeding. No infringement or invalidity finding has been made.
Procedural — no merits rulingVifor’s six-patent Hatch-Waxman action survives intact
Consolidation does not concede or waive any of Vifor’s patent claims. All six asserted patents remain in dispute in the consolidated proceeding. For Vifor, consolidation may streamline discovery and claim construction across multiple ANDA filers, potentially improving litigation efficiency while maintaining the 30-month statutory stay that may block MSN’s generic launch.
Patent rights preservedMSN faces combined proceedings alongside potential co-defendants
MSN Laboratories consented to consolidation, which is consistent with coordinating with other ANDA respondents to share invalidity and non-infringement arguments. However, consolidated proceedings can also raise litigation costs and complexity for generic challengers. MSN’s ANDA approval and commercial launch timeline remain subject to the outcome of the consolidated case.
ANDA launch remains at riskIV iron generic entry timeline remains uncertain
Injectafer® is a high-value IV iron product used in iron deficiency anaemia. With six patents in play spanning formulation and method claims, generic entry faces a multi-layered IP barrier. Consolidation typically accelerates coordinated resolution — whether through settlement, licence, or a unified merits decision — but the timeline for any generic version of ferric carboxymaltose injection reaching U.S. patients remains unclear from the public record.
Generic entry timeline unclearFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vifor (International), AG | Company | Swiss pharmaceutical IP holder — holder of US11433091B2 and five further Injectafer® patentsSearch in Eureka ↗ |
| Defendant | MSN Laboratories Private Limited | Individual | Indian generics manufacturer filing ANDA referencing Vifor’s Injectafer® ferric carboxymaltose injectionSearch in Eureka ↗ |
| Plaintiff counsel | Brian John Forsatz | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff counsel | Cynthia Stencel Betz | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff counsel | Mark M. Makhail | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff counsel | MICHAEL FREDERICK WERNO | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff law firm | Gibson, Dunn & Crutcher, LLP | Law Firm | Representing Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff law firm | Mccarter & English, LLP | Law Firm | Representing Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff law firm | QUINN EMANUAL URQUHART & SULLIVAN, LLP | Law Firm | Representing Vifor (International), AGSearch in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Court’s consolidation order is purely procedural, entered on consent with no finding on the merits of infringement or invalidity. The reference to ‘good cause shown’ and unanimous party consent reflects coordinated docket management rather than any substantive adjudication. Neither Vifor’s patent claims nor MSN’s defences have been assessed. The operative legal and factual disputes — including infringement, claim construction, and validity of all six asserted patents — remain fully open in the consolidated proceeding.
US11433091B2 and five further patents — ferric carboxymaltose IV iron formulations
The six asserted patents — US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2 — collectively cover the composition, formulation, and therapeutic application of ferric carboxymaltose, the active ingredient in Injectafer®. The portfolio spans application dates ranging from the mid-2000s through the early 2020s, reflecting a sustained prosecution strategy. Ferric carboxymaltose is a polynuclear iron(III)-hydroxide 4(R)-[(3-amido-propyl)-amino]-4-deoxy-d-gluconate complex used for intravenous iron replacement in iron deficiency anaemia where oral iron is insufficient.
This six-patent portfolio represents a commercially significant IP barrier in the U.S. IV iron market. Injectafer® competes with other IV iron formulations such as Feraheme and Venofer, and generic entry would significantly pressure pricing and market share. The breadth of claim types across the portfolio — spanning structural composition, manufacturing process, and method-of-treatment claims — means a generic challenger must successfully invalidate or design around multiple independent claim families. This multi-layered architecture is common for high-revenue specialty injectables and substantially raises the barrier to generic market entry.
Should you run an FTO analysis against Vifor’s ferric carboxymaltose patents?
Any pharmaceutical company developing, formulating, or commercialising intravenous iron replacement products — particularly ferric carboxymaltose-based injectables — should prioritise freedom-to-operate analysis against this six-patent portfolio. The assertion of patents spanning composition, formulation, and method-of-treatment claims means that even minor formulation modifications may not avoid infringement exposure. ANDA filers, CDMO partners, and branded competitors in adjacent IV iron categories are all potentially within scope.
PatSnap Eureka’s FTO Search Agent can map your iron formulation candidate against the full claim scope of US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2 simultaneously — identifying blocking claims, prosecution history estoppel, and design-around opportunities. Eureka’s prior art analysis tools also help benchmark validity risk across the portfolio before committing to ANDA filing or product launch decisions.
Run a freedom-to-operate analysis on US11433091B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ferric carboxymaltose patent cases in U.S. district courts
Explore related Hatch-Waxman ANDA patent infringement cases in the D.N.J. and other U.S. district courts involving ferric carboxymaltose and IV iron injectable formulation patents.
What this case signals for the IV iron and pharmaceutical IP landscape
A six-patent Hatch-Waxman filing in New Jersey consolidated within 82 days carries specific signals for pharma IP strategy and generic drug market access.
Layered patent portfolios are the primary defence against ANDA generic entry
Vifor’s deployment of six patents across composition, formulation, and method claims for a single IV iron product reflects standard blockbuster pharmaceutical IP strategy. Each patent layer independently triggers Hatch-Waxman litigation rights and potential 30-month stays. Companies holding IV iron or complex injectable formulation patents should audit coverage depth across claim types to maximise enforcement leverage.
Rapid consolidation signals a multi-filer ANDA environment around Injectafer®
Consolidation within 82 days of filing strongly suggests that MSN is not the only ANDA filer targeting Injectafer®. Patent holders and competitors alike should monitor the consolidated docket for additional defendants, which would reveal the full scope of generic competition entering this space and inform both enforcement and market-entry planning.
Vifor v MSN — key questions answered
Vifor (International) AG filed a patent infringement action against MSN Laboratories in the D.N.J. on April 25, 2025, asserting six patents covering Injectafer® ferric carboxymaltose injection. The case was closed on July 16, 2025 — after 82 days — when the parties jointly requested and obtained consolidation with related matters. No merits ruling on infringement or invalidity was issued.
Vifor asserted six U.S. patents: US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2. These patents collectively cover ferric carboxymaltose formulation compositions, manufacturing processes, and method-of-treatment claims for intravenous iron replacement therapy. The breadth of the portfolio is consistent with a layered Hatch-Waxman enforcement strategy.
Consolidation under Fed. R. Civ. P. 42(a) merges two or more cases with common legal or factual questions into a single proceeding. In Hatch-Waxman litigation, consolidation is common when multiple generic manufacturers file ANDAs for the same branded drug. The standalone docket closes, but all patent claims and defences remain live. A single set of pretrial proceedings — including claim construction — typically governs all consolidated defendants.
No. Consolidation is a procedural step and does not resolve the underlying patent dispute. MSN’s ability to commercialise its ANDA products depends on the outcome of the consolidated litigation or the expiry of any applicable 30-month Hatch-Waxman stay. Until the patents are found invalid, unenforceable, or not infringed — or a licence is agreed — MSN’s generic launch remains subject to patent risk.
Injectafer® (ferric carboxymaltose injection) is a high-revenue specialty IV iron product used in iron deficiency anaemia. Brand pharmaceutical companies often build multi-patent portfolios around such products spanning composition, formulation, and method-of-treatment claims. Each listed Orange Book patent independently triggers Hatch-Waxman litigation rights and potential 30-month regulatory stays, creating overlapping IP barriers that generic entrants must overcome before market entry.
PatSnap Eureka searches patents and litigation data to answer instantly.